Browsing Tag
immunology
24 posts
Why Leo Pharma’s completed Spevigo deal with Boehringer could reshape rare skin disease care
Leo Pharma completes its acquisition of Spevigo® from Boehringer Ingelheim. Learn how this rare disease drug strengthens its dermatology growth strategy.
Inside the $6bn bet: How XtalPi and DoveTree plan to reshape drug discovery with AI and robotics
XtalPi and DoveTree strike a US$6 billion AI drug discovery deal blending quantum simulation, robotics, and biology to target complex diseases.
AbbVie to acquire Capstan Therapeutics for $2.1bn to expand in vivo CAR-T platform for autoimmune therapy
AbbVie will acquire Capstan Therapeutics for $2.1B, gaining in vivo CAR-T platform and lead asset CPTX2309 in autoimmune therapy. Read full acquisition details.
Can Merck rebuild its cardiovascular empire post-Keytruda? A closer look at its next decade of drug growth
With Keytruda’s patent expiry nearing, Merck is betting on enlicitide and sotatercept to build a new cardiovascular empire. Can it succeed?
Johnson & Johnson’s $55bn bet: What it means for healthcare and investors
Johnson & Johnson is investing $55 billion in U.S. manufacturing, R&D, and technology, reinforcing its leadership in pharmaceuticals. Find out more.
The Most Effective Ways to Diagnose HIV: What You Need to Know!
Human Immunodeficiency Virus (HIV) is a serious infection that attacks the body’s immune system. Early detection and diagnosis…
Johnson & Johnson strikes $1.2bn deal with Numab Therapeutics for atopic dermatitis candidate
In a significant move to enhance its immunology offerings, Johnson & Johnson (NYSE: JNJ) has announced a definitive…
Eli Lilly completes $2.4bn acquisition of DICE Therapeutics
Eli Lilly and Company (Lilly) has finalized its acquisition of DICE Therapeutics, Inc. (NASDAQ: DICE) for $2.4 billion,…
AbbVie, Calibr to drive preclinical and clinical advancements in expanded partnership
AbbVie and Scripps Research institute’s division Calibr have announced a broadened strategic collaboration targeted at developing preclinical and…
Acelyrin boosts immunology pipeline through acquisition of ValenzaBio
Acelyrin has acquired ValenzaBio, a privately held clinical-stage biopharmaceutical company, in an all-stock deal. With the acquisition of…